Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy

This is a clinical observation of a patient treated for metastatic head and neck cancer with mesenchymal stem cells mediated prodrug gene therapy. The cells were applied intravenously. We did not observe any therapeutic effect. However, a temporal bicytopenia was observed. Key Words: metastatic head and neck cancer, therapeutic stem cells, blood counts

Phylogeographic perspective on the distribution and dispersal of a marine pathogen, the oyster parasite Bonamia exitiosa

The significance of infectious disease has intensified as our marine ecosystems are increasingly altered, with molluscan taxa being among the affected. One of the important pathogens to emerge in recent years, the oyster parasite Bonamia exitiosa,has a broad geographic distribution and has been found to infect a number of oyster species. In order to better understand how B. exitiosa achieved this wide distribution, a gene genealogy was constructed using internal transcribed spacer region ribosomal DNA sequencing data from across the host species range.The analysis revealed population structure in the form of 4 well-defined groups of sequences: 3corresponding to geographic regions (temperate Atlantic and Pacific waters of the Southern Hemisphere, California, and the western Atlantic along the coast of the Americas) and the fourth geographically cosmopolitan. Inclusion of B. exitiosa sequences from New Zealand, Australia, and Argentina in the Southern Hemisphere group may reflect natural dispersal of the parasite via raft-ing with oyster hosts, whereas the California group may reflect limited anthropogenic movement of a host species, Ostrea lurida. The extensive geographic distribution of B. exitiosa parasites belonging to the cosmopolitan and Atlantic Coast groups may relate to both natural and anthropogenic dispersal of a single host, O. stentina, which is distributed from the eastern Americas tothe Mediterranean and African coast to New Zealand — that is, in most regions where B. exitiosa has been found to occur

Integrated motor drives: state of the art and future trends

With increased need for high power density, high efficiency and high temperature capabilities in Aerospace and Automotive applications, Integrated Motor Drives (IMD) offers a potential solution. However, close physical integration of the converter and the machine may also lead to an increase in components temperature. This requires careful mechanical, structural and thermal analysis; and design of the IMD system. This paper reviews existing IMD technologies and their thermal effects on the IMD system. The effects of the power electronics (PE) position on the IMD system and its respective thermal management concepts are also investigated. The challenges faced in designing and manufacturing of an IMD along with the mechanical and structural impacts of close physical integration is also discussed and potential solutions are provided. Potential converter topologies for an IMD like the Matrix converter, 2-level Bridge, 3-level NPC and Multiphase full bridge converters are also reviewed. Wide band gap devices like SiC and GaN and their packaging in power modules for IMDs are also discussed. Power modules components and packaging technologies are also presented

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Background:The randomised phase III TURANDOT trial compared first-line bevacizumab-paclitaxel (BEV-PAC) vs bevacizumab-capecitabine (BEV-CAP) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). The interim analysis revealed no difference in overall survival (OS; primary end point) between treatment arms; however, progression-free survival (PFS) and objective response rate were significantly superior with BEV-PAC. We sought to identify patient populations that may be most appropriately treated with one or other regimen.Methods:Patients with HER2-negative LR/mBC who had received no prior chemotherapy for advanced disease were randomised to either BEV-PAC (bevacizumab 10 mg kg-1 days 1 and 15 plus paclitaxel 90 mg m-2 days 1, 8 and 15 q4w) or BEV-CAP (bevacizumab 15 mg kg-1 day 1 plus capecitabine 1000 mg m-2 bid days 1-14 q3w). The study population was categorised into three cohorts: triple-negative breast cancer (TNBC), high-risk hormone receptor-positive (HR+) and low-risk HR+. High- and low-risk HR+ were defined, respectively, as having 2 vs 1 of the following four risk factors: disease-free interval 24 months; visceral metastases; prior (neo)adjuvant anthracycline and/or taxane; and metastases in 3 organs.Results:The treatment effect on OS differed between cohorts. Non-significant OS trends favoured BEV-PAC in the TNBC cohort and BEV-CAP in the low-risk HR+ cohort. In all three cohorts, there was a non-significant PFS trend favouring BEV-PAC. Grade 3 adverse events were consistently less common with BEV-CAP.Conclusions:A simple risk factor index may help in selecting bevacizumab-containing regimens, balancing outcome, safety profile and patient preference. Final OS results are expected in 2015 (ClinicalTrials.gov NCT00600340).British Journal of Cancer advance online publication, 30 September 2014; doi:10.1038/bjc.2014.504 www.bjcancer.com